UCB in the news
Developing innovative therapies
Tamtam found 20 recent articles about UCB.
- UCB stock: Kygevvi approval meets fresh BIMZELX evidence
UCB received EU approval for Kygevvi for TK2d and presented new positive clinical data for BIMZELX in psoriatic arthritis, noting a safety consideration.
- UCB stock: Kygevvi wins EU approval for rare TK2d disease
UCB's Kygevvi secured EU approval for thymidine kinase 2 deficiency, enhancing its rare-disease treatment offerings.
- UCB stock gets EU approval for Kygevvi in rare TK2d disease
UCB obtained EU approval for Kygevvi, its first therapy for the rare genetic disorder TK2d.
- UCB's Emmanuel Caeymaex: head-to-head proof, younger patients and a multi-pathway bet on galvokimig
UCB is advancing its immunology pipeline, focusing on bimekizumab's evidence base and exploring its multispecific antibody galvokimig.
- UCB Announces 11 Inaugural Recipients of Annual Hidradenitis Suppurativa Scholarship™
UCB announced 11 inaugural recipients of its annual Hidradenitis Suppurativa Scholarship, providing up to $10,000 per recipient to support educational and career goals for individuals affected by HS.
- Beursupdate: Melexis en UCB trekken de kar in groene Bel20
The Brussels stock exchange saw gains led by Melexis and UCB, while Nvidia's stock dropped due to CEO scandal reports, and Umicore announced a significant investment and job cuts.
- Veeva Systems (VEEV) Wins UCB For Vault CRM, Is The Stock Still Cheap?
Veeva Systems gained UCB as a Vault CRM client, driving stock momentum, yet its valuation sparks debate between cash flow undervaluation and a high P/E ratio.
- UCB stock weighs stronger BIMZELX PsA data against safety signals
UCB's BIMZELX treatment demonstrated stronger joint-response rates than risankizumab in a Phase 3b psoriatic arthritis trial, despite some safety signals.
- UCB stock weighs BIMZELX joint gains against Candida caveat
UCB's BIMZELX demonstrated superior joint-response rates against risankizumab in a Phase 3b trial for psoriatic arthritis, despite a higher incidence of mild Candida infections.
- UCB continues reign as largest drug ad spender as Bimzelx once again tops the ranks
UCB's Bimzelx maintained its lead in drug ad spending for October, allocating $66.2 million with a majority on streaming, followed by Johnson & Johnson's Tremfya and AbbVie's Skyrizi.
- UCB: Bimzelx Retains Its Edge Over Skyrizi at 24 Weeks, on an Exploratory Endpoint
Bimzelx showed superior efficacy over Skyrizi in treating psoriatic arthritis at 24 weeks on an exploratory endpoint, with more frequent Candida infections.
- 'Seal of approval': Rowen seeks more companies after UCB commitment
UCB joined Rowen, prompting the development's foundation to seek more companies and a new leader.
- De ankeraandeelhouders achter UCB: de voorbeeldige miljardairsfamilie Janssen
The article profiles the exemplary billionaire Janssen family, anchor shareholders of UCB.
- UCB’s Bimzelx leads pharma’s Q3 drug ad spend, but who will take the annual prize?
UCB's immunology drug Bimzelx became the top drug ad spender in Q3 2026, primarily due to increased streaming ad placements, challenging annual leaders Skyrizi and Tremfya.
- Beursblik: Jefferies verhoogt koersdoel UCB
Jefferies raised UCB's price target to •250 and maintained a 'Hold' rating after UCB increased its 2026 revenue and EBITDA forecasts.
- UCB verhoogt zijn vooruitzichten. De koers schiet omhoog!
UCB has increased its revenue growth forecast to over 20% and EBITDA growth to 40-45% for the second time this year, driven by strong drug sales.
- Bel20 uitblinker op rode Europese beurzen, met dank aan jump van UCB
The Bel20 index was a strong performer on otherwise negative European exchanges, primarily due to UCB's significant jump.
- Brusselse beurs krijgt zuurstofinjectie van UCB
UCB raised its 2026 outlook due to strong performance of Bimzelx and Cimzia, leading to a significant increase in its stock and positively impacting the Bel20 index.
- Farmatoppers UCB en Argenx scheren allebei hoge toppen, maar de belegger reageert compleet anders
Argenx and UCB report strong drug sales for Vyvgart and Bimzelx, respectively, leading to differing stock market reactions with Argenx shares falling and UCB shares rising.
- UCB verhoogt outlook voor 2026
UCB increased its 2026 financial outlook, raising revenue and EBITDA growth forecasts, driven by strong sales of Bimzelx and Cimzia.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like UCB?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies